Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa

Journal of Infectious Diseases

Volumn 202, Issue 10, 2010, Pages 1585-1592

  Herrmann, Gloria ^a   Yang, Liang ^b   Wu, Hong ^c   Song, Zhijun ^c   Wang, Hengzhuang ^c   Høiby, Niels ^c   Ulrich, Martina ^a   Molin, Søren ^b   Riethmüller, Joachim ^a   Döring, Gerd ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; TOBRAMYCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BIOFILM; BRONCHUS OBSTRUCTION; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SPUTUM; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; COLISTIN; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, INBRED LEW; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 78349232036     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656788     Document Type: Article

References (38)

1. Hodson ME, Geddes D, Bush A. Cystic fibrosis, 3rd ed. Part 2. London: Hodder Arnold, 2007.
2. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95:1005-10.
3. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317-25.
4. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003; 361:681-9.
5. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry 2005 annual data report. Bethesda, MD: Cystic Fibrosis Foundation, 2006.
6. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914-21.
7. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30.
8. Hoiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Hodson ME, Geddes D, eds. Cystic fibrosis. London: Arnold, 2000:83-108.
9. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32:277-87.
10. Döring G, Hoiby N, for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3:67-91.
11. Wimpenny J, Manz W, Szewzyk U. Heterogeneity in biofilms. FEMS Microbiol Rev 2000; 24:661-71.
12. Xu KD, Stewart PS, Xia F, Huang CT, McFeters GA. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microbiol 1998; 64:4035-9.
13. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-4.
14. Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L, Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007; 195:70-80.
15. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-71.
16. Döring G, Conway SP, Heijerman HGM, Hodson ME, Høiby N, Smyth A, Touw DJ, for the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16:749-67.
17. Ghani M, Soothill JS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can J Microbiol 1997; 43:999-1004.
18. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis 1985; 4:172-7.
19. Smith AL, Doershuk C, Goldmann D, et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413-21.
20. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68:223-40.
21. Klausen M, Aaes-Jørgensen A, Molin S, Tolker-Nielsen T. Involvement of bacterial migration in the development of complex multicellular structures in Pseudomonas aeruginosa biofilms. Mol Microbiol 2003; 50:61-8.
22. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanosulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:781-5.
23. Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A. Pharmakodynamic interactions of antibiotics alone and in combinations. Clin Infect Dis 1998; 27:40-6.
24. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37:1771-6.
25. Sternberg C, Tolker-Nielsen T. Growing and analyzing biofilms in flow cells. Curr Protoc Microbiol 2006; chapter 1:unit 1B.2.
26. Pamp SJ, Tolker-Nielsen T. Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa. J Bacteriol 2007; 189:2531-9.
27. Pedersen SS, Shand GH, Hansen BL, Hansen GN. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS 1990; 98:203-11.
28. Cash HA, Woods DE, McCullough B, Johanson WE Jr, Bass JA. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 1979; 119:453-9.
29. Hoppe JE, Theurer-Mainka U, Stern M. Comparison of three methods for culturing throat swabs from cystic fibrosis patients. J Clin Microbiol 1995; 33:1896-8.
30. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol 1995; 49:711-45.
31. Haagensen JA, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, Molin S. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007; 189:28-37.
32. Park MK, Myers RA, Marzella L. Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. Clin Infect Dis 1992; 14:720-40.
33. Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317-23.
34. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426:306-10.
35. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-64.
36. Govan JRW. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002; 1:S203-8.
37. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997; 64:748-52.
38. Davies JD, Hall P, Francis J, et al. A dry powder formulation of colistimethate sodium is safe and well tolerated in adults and children with CF. Pediatr Pulmonol 2004; S27:A278.